Education
About Us
Working with TipRanks
Follow Us
Dyne Therapeutics (DYN)
NASDAQ:DYN
Total Valuation
Dyne Therapeutics has a market cap or net worth of $3.16B. The enterprise value is $1.12B.
Market Cap$3.16B
Enterprise Value$1.12B
Share Statistics
Dyne Therapeutics has 161,805,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding161,805,160
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Dyne Therapeutics’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -52.21%.
Return on Equity (ROE)-0.50
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-52.21%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee0.00
Profits Per Employee-1.65M
Employee Count192
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dyne Therapeutics is ―. Dyne Therapeutics’s PEG ratio is 0.48.
PE Ratio―
PS Ratio0.00
PB Ratio3.52
Price to Fair Value3.52
Price to FCF-7.53
Price to Operating Cash Flow-6.41
PEG Ratio0.48
Income Statement
In the last 12 months, Dyne Therapeutics had revenue of 0.00 and earned -317.42M in profits. Earnings per share was -3.37.
Revenue0.00
Gross Profit-2.24M
Operating Income-343.89M
Pretax Income-317.42M
Net Income-317.42M
EBITDA-315.18M
Earnings Per Share (EPS)-3.37
Cash Flow
In the last 12 months, operating cash flow was -375.71M and capital expenditures -21.30M, giving a free cash flow of -397.01M billion.
Operating Cash Flow-375.71M
Free Cash Flow-397.01M
Free Cash Flow per Share-2.45
Dividends & Yields
Dyne Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.81
52-Week Price Change-23.05%
50-Day Moving Average19.38
200-Day Moving Average13.37
Relative Strength Index (RSI)45.83
Average Volume (3m)3.12M
Important Dates
Dyne Therapeutics upcoming earnings date is Feb 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
Dyne Therapeutics as a current ratio of 15.60, with Debt / Equity ratio of 3.90%
Current Ratio15.60
Quick Ratio15.60
Debt to Market Cap<0.01
Net Debt to EBITDA1.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Dyne Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Dyne Therapeutics EV to EBITDA ratio is -5.73, with an EV/FCF ratio of -6.13.
EV to Sales0.00
EV to EBITDA-5.73
EV to Free Cash Flow-6.13
EV to Operating Cash Flow-6.18
Balance Sheet
Dyne Therapeutics has $791.89M in cash and marketable securities with $21.32M in debt, giving a net cash position of $770.57M billion.
Cash & Marketable Securities$791.89M
Total Debt$21.32M
Net Cash$770.57M
Net Cash Per Share$4.76
Tangible Book Value Per Share$6.69
Margins
Gross margin is -39.19%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-39.19%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Dyne Therapeutics is $38.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$38.40
Price Target Upside103.17% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast―
EPS Growth Forecast-2.75%